A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis

Investigator: Sheetal Shroff, MD

Study Coordinator:

Status: Enrolling

ClinicalTrials.gov Number: NCT03971422


Protocol Number: Pro00022515


The purpose of the MycarinGstudy is to demonstrate the clinical efficacy and to assess safety and tolerability of rozanolixizumab in patients with generalized myasthenia gravis (MG). NCT number: NCT03971422
More to Explore